ASPAC III Acquisition Corp., a British Virgin Islands-incorporated SPAC, raised approximately $60 million in its November 2024 IPO, funds held in trust pending business combination. The company has no operating revenues and incurs administrative costs typical of pre-combination SPACs. In May 2025, ASPAC III entered a stock-for-stock merger agreement with Bioserica International Limited, valued at roughly $218 million, marking a strategic pivot into the ESG-aligned bio-based antimicrobial materials sector. The SPAC's financials reflect widening operating losses but a positive net income largely driven by non-operating accounting adjustments. Key risks remain around closing the transaction by the November 2026 deadline. Post-merger success depends on operational integration and growth execution.